The following represents disclosure information provided by authors of this abstract. The Gastrointestinal Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A phase II study of capecitabine in combination with erlotinib as first-line therapy in patients with metastatic pancreatic cancer (stage IV).
Sonia Candamio Folgar
Disclosure not yet available
Carlos Méndez Méndez
Disclosure not yet available
Mónica Jorge Fernández
Disclosure not yet available
Carlos Romero Reinoso
Disclosure not yet available
Guillermo Quintero-Aldana
Disclosure not yet available
Mercedes Salgado Fernández
Disclosure not yet available
Juan de la Cámara Gómez
Disclosure not yet available
Margarita Reboredo López
Disclosure not yet available
Manuel Ramos Vazquez
Disclosure not yet available
Rafael Lopez
Disclosure not yet available